Sex Differences in Cannabis Sensitivity

Photo Credit: Ihon Karwan

Scientific Frontline: Extended "At a Glance" Summary: Sex Differences in Cannabis Sensitivity

The Core Concept: A controlled clinical study indicates that men who occasionally use cannabis experience stronger acute physiological and psychoactive effects than women with comparable use habits, despite possessing similar blood tetrahydrocannabinol (THC) levels.

Key Distinction/Mechanism: Unlike prior pooled studies and animal models that suggested higher female sensitivity, this controlled trial isolated the interaction between biological sex and use frequency. It demonstrated that occasional male users experience greater sedation, impairment, and heart rate elevation than their female counterparts, suggesting that women may build physiological tolerance more rapidly.

Origin/History: The research was conducted by the UCLA Center for Cannabis and Cannabinoids and published in Neuropsychopharmacology in November 2026.

Major Frameworks/Components:

• The interaction between biological sex and frequency of use on acute, short-term cannabis effects.
• Controlled hormonal baselines, achieved by testing female participants during the identical menstrual phase and excluding those on hormonal birth control.
• Evaluation of subjective psychoactive responses (e.g., anxiety, sedation) and physiological markers (e.g., heart rate, blood THC concentration).
• Trajectories of tolerance acquisition and susceptibility to cannabis use disorder.

Heart-in-a-Dish Tech Enables Personalized Heart Disease Care

Prof. Terry Hébert and Giada Castagnola
Photo Credit: Owen Egan / Joni Dufour.

Scientific Frontline: Extended "At a Glance" Summary: "Heart-in-a-Dish" Technology for Dilated Cardiomyopathy

The Core Concept: Researchers have developed an in vitro model that reprograms a patient's blood cells into stem cells, and subsequently into genetically identical heart muscle cells, to simulate heart disease.

Key Distinction/Mechanism: Unlike conventional one-size-fits-all treatments, this approach combines human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) with advanced microscopy to evaluate the signaling and functional landscape at the single-cell level, identifying patient-specific physiological differences.

Major Frameworks/Components:

• Cellular reprogramming of blood samples into functional, miniature beating heart tissues.
• Single-cell microscopic evaluation of cardiomyocyte physiology.
• Comparative analysis of sex-based hormonal responses in failing heart tissue.

Novel Coronavirus RNA-Protein Targets

High-resolution microscopic visualization of a coronavirus particle highlighting intricate RNA and protein structures.
Image Credit: Scientific Frontline / AI generated

Scientific Frontline: Extended "At a Glance" Summary: Coronavirus RNA-Protein Interactions

The Core Concept: Researchers have mapped the intricate interactions between viral RNA and the proteins responsible for coronavirus replication and regulation. By identifying these highly conserved RNA binding sites, scientists have uncovered new fundamental molecular targets for variant-resistant antiviral treatments.

Key Distinction/Mechanism: Unlike current treatments that target highly mutable viral features, this approach uses enhanced cross-linking and immunoprecipitation (eCLIP) to map the entire viral genome. It targets essential, underlying molecular machinery that is conserved across coronavirus species, making it exceedingly difficult for the virus to evade the therapy through mutation.

Major Frameworks/Components:

• Enhanced cross-linking and immunoprecipitation (eCLIP): A genome-scale mapping technique used to survey and identify unexpected RNA-protein interaction sites across the entire viral genome.
• Target proteins: The research identified critical RNA binding sites for primase cofactor (NSP8), RNA-dependent RNA polymerase (NSP12), and the nucleocapsid (N) protein.
• The 5′ untranslated region: A complex RNA structure at the beginning of the genome that interacts with the N protein to regulate translation.
• Locked nucleic acids (LNAs): Short, modified nucleic acid sequences deployed to bind specific RNA regions, successfully blocking protein interactions and significantly reducing viral replication in animal cells and human lung cells.

Psilocybin Effects in Mouse Models

Researchers from UC Berkeley, UCSF and Stanford ran parallel trials of psilocybin, a hallucinogen found in some mushrooms, to see what behavioral effects were reproducible in mice.
Illustration Credit: Angela Shang

Scientific Frontline: Extended "At a Glance" Summary: Reproducibility of Psilocybin Effects in Mice

The Core Concept: A multi-institutional collaboration across five neuroscience laboratories aimed to establish a baseline of reproducible behavioral effects of the hallucinogen psilocybin in mice. By pooling data from identical, parallel trials, researchers sought to isolate robust behavioral changes from experimental noise and publication bias.

Key Distinction/Mechanism: Unlike traditional single-laboratory studies that often yield conflicting results due to variable environmental contexts and assays, this parallel methodology standardized protocols across independent sites. The study found that while acute behavioral changes, such as head twitching and heightened anxiety, were universally reproducible 10 minutes post-injection, previously reported long-term effects on depression and sociability were not.

Origin/History: The parallel experimental trials commenced in 2022 following a year of federal approval processes for psilocybin use, with the combined findings published in the November 2, 2026, issue of the journal Nature Neuroscience.

Major Frameworks/Components:

• Acute Behavioral Alterations: Replicable effects include head twitching, increased anxiety, and avoidance behavior immediately following the administration of a single dose of 2 milligrams per kilogram of psilocybin.
• Absence of Long-Term Behavioral Changes: The pooled data demonstrated no lasting behavioral changes, such as reduced depressive symptoms or modified fear responses, 24 hours after dosing.
• Environmental and Methodological Variability: Differences in outcomes across independent laboratories were linked to subtle variations in handler sex, acclimation time, mouse supplier, enclosure size, and the time of day the drugs were administered.

Neurotoxicology: In-Depth Description

Neurotoxicology is the scientific study of the adverse effects of chemical, biological, or physical agents on the structure or function of the central and peripheral nervous systems. Its primary goal is to understand how environmental, industrial, and pharmaceutical toxins interact with neural tissue to cause acute or chronic damage, altering neurodevelopment, neurotransmission, and overall neurobehavioral health.

Hippo Pathway Mutations and Immune Evasion

Schematic of YAP/TAZ-mediated immune evasion. YAP/TAZ hyperactivation is associated with genomic instability that may make cancer cells more recognizable to CD8+ T cells, immune cells that can recognize and kill abnormal cells, including cancer cells. At the same time, YAP/TAZ hyperactivation can increase PD-L2, which binds to PD-1 receptors on CD8+ T cells and suppresses their attack. Together, these effects may help explain why certain Hippo pathway alterations were linked to better outcomes following immune checkpoint inhibitor therapy.
Image Credit: Toshinori Ando/Hiroshima University

Scientific Frontline: Extended "At a Glance" Summary: Hippo Pathway Dysregulation and PD-L2-Mediated Immune Evasion

The Core Concept: Hyperactive YAP and TAZ proteins, driven by dysregulation in the Hippo signaling pathway, simultaneously induce genomic instability that flags cancer cells to the immune system and increase PD-L2 expression to suppress targeted T-cell attacks.

Key Distinction/Mechanism: Unlike typical immune evasion mechanisms, YAP/TAZ hyperactivation creates a paradoxical state where tumors are highly recognizable to CD8+ T cells due to DNA damage, yet remain protected because elevated PD-L2 binds to PD-1 receptors on the T cells, effectively neutralizing the immune response.

Origin/History: Detailed in a recent study published in Communications Biology by Hiroshima University researchers and international collaborators, this mechanism was identified by analyzing laboratory cancer models and clinical data from 1,662 patients treated with immune checkpoint inhibitors.

Major Frameworks/Components:

• The Hippo signaling pathway, specifically the loss of regulators LATS1 and LATS2, which unleashes YAP/TAZ activity.
• CD8+ T cells, which recognize and target abnormal cells exhibiting high mutational burdens.
• PD-L2, an immune checkpoint ligand regulated by TEAD and BRD4 that binds to PD-1 receptors on T cells to inhibit their lethal function.
• Head and neck squamous cell carcinoma (HNSCC), the primary cancer model used to test engineered T-cell vulnerability.

RuPHOTACs: Light Cages for Targeted Drug Therapies

General design of photocaged RuPHOTACs.
Image Credit: Phoebe Glazer

Scientific Frontline: Extended "At a Glance" Summary: RuPHOTACs (Ruthenium-based Photoactivated Chimeras)

The Core Concept: RuPHOTACs are light-activated molecular cages that keep protein-degrading drug molecules inactive until they are exposed to low-energy red light.

Key Distinction/Mechanism: While conventional proteolysis-targeting chimeras (PROTACs) degrade both diseased and healthy proteins systemically, RuPHOTACs utilize a ruthenium metal complex to physically block the drug from acting. Upon exposure to red light, the ruthenium cage is removed, allowing the PROTAC to selectively bind to disease-causing proteins and trigger their destruction only in the illuminated tissue.

Major Frameworks/Components:

• PROteolysis-Targeting Chimeras (PROTACs): Bifunctional catalyst molecules that simultaneously bind to a target protein and an E3 ubiquitin ligase enzyme, tagging the protein for natural cellular degradation.
• Ruthenium Photocages: A complex utilizing ruthenium, a transition metal, to block protein interactions until triggered by red light.
• Dendra2 Fusion Reporter System: A novel analytical strategy using a photoconvertible protein to accurately monitor and decouple true protein degradation rates from new protein synthesis in live, intact cells.

p53 Protein Boosts T-Cell Immunotherapy Efficacy

T cells (black) attack melanoma cells (red). Compared with the control group (left), T cells treated with navtemadlin were significantly more effective at killing melanoma cells, leaving very few cancer cells remaining.
Image Credit: Crompton Laboratory.

Scientific Frontline: Extended "At a Glance" Summary: p53 Activation in T-Cell Immunotherapy

The Core Concept: Temporarily activating the p53 protein during the preparation of engineered T cells enhances their resilience, reduces immune exhaustion, and significantly improves their ability to destroy tumor cells.

Key Distinction/Mechanism: Rather than introducing additional genetic modifications to boost immune cell longevity, this method uses an investigational drug called navtemadlin to block MDM2, a protein that normally suppresses p53. This temporary activation promotes the development of robust central memory T cells with higher energy reserves and increased production of cancer-fighting proteins like interferon-gamma and granzyme B.

Origin/History: Published in Frontiers in Immunology by UCLA Health researchers in October 2026, this research marks one of the first human studies to connect p53—traditionally known as the "guardian of the genome," due to its role in preventing cancer—with the prevention of T-cell exhaustion.

Major Frameworks/Components:

• Engineered T-Cell Therapies: Customizing a patient's own immune cells, such as through chimeric antigen receptor (CAR) T-cell therapy and T-cell receptor (TCR) therapy, to target tumors.
• T-Cell Exhaustion: The gradual loss of immune cell efficacy and ability to multiply following repeated exposure to cancer cells.
• p53 and MDM2 Regulation: The molecular pathway where inhibiting MDM2 temporarily boosts p53 activity to optimize T-cell maturation and metabolic capacity.

Huntington's Disease: Widespread Genetic Mechanism

 A new study revealed that aggregations of the huntingtin protein (pink) occur within nuclei (blue) of cells with highly expanded DNA repeats in both the striatum and neocortex of individuals with Huntington's disease.
Image Credit: Courtesy of the McCarroll lab

Scientific Frontline: Extended "At a Glance" Summary: Widespread DNA Repeat Expansion in Huntington's Disease

The Core Concept: Recent research indicates that the pathogenic expansion of inherited DNA repeats associated with Huntington's disease causes cellular toxicity in both the striatum and the neocortex.

Key Distinction/Mechanism: While the mutated HTT gene expands slowly throughout a patient's life, it becomes toxic only after accumulating approximately 150 trinucleotide repeats; however, this expansion occurs at a significantly slower rate and triggers distinct gene expression changes in the neocortex compared to the striatum.

Origin/History: The genetic basis of Huntington's disease has been recognized for decades, but a foundational 2025 study first identified the 150-repeat toxicity threshold in the striatum, which was subsequently confirmed in the neocortex by an October 2026 study published in the journal Cell.

Major Frameworks/Components:

• Somatic DNA-repeat expansion: The progressive elongation of the inherited trinucleotide sequence within the HTT gene over a patient's lifetime.
• Toxic threshold: A critical limit of approximately 150 DNA repeats, which initiates severe molecular dysfunction and eventual cell death once surpassed.
• Nuclear inclusions: Sparse aggregations of the Huntingtin protein within the nuclei of near-death cells, acting as a terminal marker of cellular failure rather than the primary driver of toxicity.
• Differential regional vulnerability: The varying rates of repeat expansion and unique transcriptomic alterations that explain why the disease affects distinct regions of the brain at different times.

Marine Molecule Targets Brain-Eating Amoeba

Naegleria fowleri, a brain-eating amoeba, is one of the most lethal infections in the world. Scientists at UC San Diego have isolated a molecule that could help us fight back.
Image Credit: Scientific Frontline / AI generated

Scientific Frontline: Extended "At a Glance" Summary: Rutamycin B and Primary Amoebic Meningoencephalitis

The Core Concept: Rutamycin B is a potent marine-derived compound that demonstrates rapid and selective efficacy against Naegleria fowleri, the parasitic amoeba responsible for the highly lethal brain infection known as primary amoebic meningoencephalitis (PAM).

Key Distinction/Mechanism: While standard treatments like amphotericin B can be slow-acting and highly toxic, rutamycin B works by shutting down the parasite's energy-producing enzymes, reaching full potency in just four hours, and is 200 to 300 times more lethal to the amoeba than to human cells.

Origin/History: In October 2026, researchers at the University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and Scripps Institution of Oceanography published their discovery of the compound's efficacy in the journal Marine Drugs.

Major Frameworks/Components:

• Enzyme inhibition: The compound targets and neutralizes specific enzymes required for the parasite's energy production.
• Therapeutic synergy: When combined with standard treatments, rutamycin B achieves equivalent efficacy using only 3 to 10 percent of the original dose.
• Structural optimization: Researchers are currently focused on evaluating the compound's ability to cross the blood-brain barrier in live disease models.

MS Treatment Rituximab Linked to Bowel Disease Risk

Image Credit: Scientific Frontline / stock image

Scientific Frontline: Extended "At a Glance" Summary: Rituximab and Inflammatory Bowel Disease Risk

The Core Concept: Rituximab, an anti-CD20 therapy frequently used to treat multiple sclerosis, is associated with a significantly increased, though absolutely low, risk of developing inflammatory bowel disease compared to other highly effective multiple sclerosis treatments.

Key Distinction/Mechanism: While highly effective at preventing multiple sclerosis relapses by targeting CD20-positive B cells, rituximab is linked to an approximately tenfold higher relative risk of inflammatory bowel disease, particularly Crohn's disease, when compared to alternative therapies like natalizumab, dimethyl fumarate, and fingolimod.

Major Frameworks/Components:

• The study analyzed data from Swedish registers covering nearly 14,000 treatment episodes in patients with relapsing-remitting multiple sclerosis.
• Researchers compared rituximab against three other therapies: natalizumab, dimethyl fumarate, and fingolimod.
• The absolute risk remains low, with fewer than 2% of patients in any treatment group developing inflammatory bowel disease within 10 years of starting treatment.
• The risk increase translates to roughly one additional case of inflammatory bowel disease for every 131 patients treated with rituximab for five years instead of an alternative treatment.

LSD Accelerates Brain Rhythms and Complexity

Doctoral student Venkatesh Subramani in the magnetoencephalography (MEG) unit at Université de Montréal, wearing a psychedelic-patterned sweater.
Photo Credit: Karim Jerbi, Using an Artificial Intelligence Tool to Modify the Sweater.

Scientific Frontline: Extended "At a Glance" Summary: LSD Brain Rhythm Modulation

The Core Concept: Lysergic acid diethylamide (LSD) is a potent psychedelic that alters brain function by simultaneously increasing the frequency of electrical rhythms and amplifying the complexity, or fractal dimension, of cortical activity.

Key Distinction/Mechanism: Previous models characterized the dampening of brain waves under psychedelics simply as "desynchronization." However, high-resolution magnetoencephalography (MEG) paired with artificial intelligence reveals that LSD actually accelerates alpha waves by approximately 2 hertz and beta waves by 5 hertz, while generating highly irregular, fractal brain signals that recur across multiple time scales.

Major Frameworks/Components:

• Magnetoencephalography (MEG): A neuroimaging technique used to map brain activity by measuring tiny magnetic fields produced by naturally occurring electrical currents in the brain.
• Alpha and Beta Oscillations: Resting (alpha) and active (beta) neuronal rhythms that increase in speed, rather than merely weakening, under the influence of LSD.
• Fractal Signal Processing: The mathematical measurement of brain activity complexity, demonstrating patterns that repeat across varied time scales, which heavily impacts sensory perception, language, and emotion centers.
• Machine Learning Algorithms: Artificial intelligence systems capable of distinguishing LSD-induced brain states from placebo states with 88 percent accuracy by isolating specific neural signatures.

Boosting Host-Directed Viral Defenses

Lindsay Grace Miller, a Washington State University graduate student in Professor Santanu Bose's lab, initiated the project that identified a cellular signaling pathway researchers used to boost antiviral defenses.
Photo Credit: Washington State University

Scientific Frontline: Extended "At a Glance" Summary: Extracellular ISG15 Antiviral Pathway

The Core Concept: The extracellular ISG15 antiviral pathway is a naturally occurring cellular signaling mechanism that boosts a host cell's innate defenses to resist infection before a virus can spread.

Key Distinction/Mechanism: Unlike traditional antiviral drugs that directly target viral proteins, this host-directed approach strengthens the cell's own protective machinery via the extracellular ISG15 protein, rendering it less vulnerable to viral mutations.

Major Frameworks/Components:

• ISG15 Protein: A cellular factor naturally induced during infection that acts outside the cell as a "booster" to activate defense pathways.
• Recombinant ISG15: A synthetic protein used to artificially amplify the pathway's activation, resulting in robust cellular resistance to pathogens.
• Host-Directed Therapeutics: A treatment strategy focusing on enhancing host cellular responses rather than targeting the virus directly.
• Broad-Spectrum Efficacy: Demonstrated protective effects against respiratory syncytial virus (RSV), influenza A, and parainfluenza viruses.

Fucoidan: Marine Antioxidant Potential

Photo Credit: PixelAnarchy

Scientific Frontline: Extended "At a Glance" Summary: Fucoidan as a Marine Antioxidant

The Core Concept: Fucoidan is a sulfated, fucose-rich polysaccharide isolated from the cell walls of brown seaweed that functions as a bioactive compound with significant antioxidant potential.

Key Distinction/Mechanism: Evolving as a complex defense mechanism for the survival of macroalgae in marine environments, fucoidan combats oxidative stress and modulates immune responses in biological systems.

Origin/History: Research over the past decade, culminating in a 2026 comprehensive review, has provided mounting evidence of its efficacy as an oxidative stress-modulating agent, paving the way for targeted translational studies.

Major Frameworks/Components:

• Immune modulation and targeted reduction of oxidative stress.
• Gut, digestive, skin, and dermal health management.
• Supplementary therapies for oncology, liver, kidney, and selected neurodegenerative diseases.

Hypoxia Pill Reverses Parkinson's in Mice

Image Credit: Credit: Susanna Hamilton

Scientific Frontline: Extended "At a Glance" Summary: Hypoxia-in-a-Pill Therapy

The Core Concept: A two-drug combination therapy designed to artificially reduce tissue oxygen levels, mimicking the therapeutic benefits of a low-oxygen environment (hypoxia) without the risks associated with continuously breathing oxygen-depleted air.

Key Distinction/Mechanism: Unlike placing subjects in physically hypoxic environments, which can lead to adverse cardiac side effects, this oral regimen utilizes the small molecule GBT601 to bind to red blood cell hemoglobin to prevent oxygen delivery, while PT2399 inhibits the HIF-2α pathway to block the body's compensatory overproduction of red blood cells.

Origin/History: First established in 2024 as a proof-of-concept by Vamsi Mootha's team at the Broad Institute, the regimen was refined into a highly effective second-generation version and published in the Proceedings of the National Academy of Sciences in October 2026.

Major Frameworks/Components:

• GBT601: A targeted molecule that increases hemoglobin's affinity for oxygen, safely restricting its release into cellular tissues.
• PT2399: An inhibitor drug targeting the HIF-2α pathway, preventing secondary compensatory responses such as the dangerous overproduction of red blood cells.
• Mitochondrial Dysfunction: The underlying cellular pathology targeted by the treatment, where malfunctioning mitochondria fail to consume oxygen properly, resulting in toxic oxygen accumulation and cellular damage.

Molecular Pharmacology: In-Depth Description

Molecular Pharmacology is the branch of pharmacology concerned with the biochemical and biophysical characteristics of interactions between drug molecules and the cellular targets of a living organism. Its primary goal is to understand the exact mechanisms of drug action at the molecular, cellular, and subcellular levels, uncovering how pharmaceutical agents bind to receptors, influence signaling pathways, and alter cellular function to produce therapeutic or toxic effects.

BCAT1 Inhibitors Prevent Heart Failure

Image Credit: Courtesy of Nagoya University

Scientific Frontline: Extended "At a Glance" Summary: BCAT1 Inhibition in Cardiac Fibrosis

The Core Concept: BCAT1 is an enzyme that drives excessive collagen production and subsequent scar tissue formation, known as fibrosis, in the heart following a heart attack. Pharmacologically blocking this enzyme reduces harmful tissue stiffening and preserves cardiac pumping function.

Key Distinction/Mechanism: Targeting BCAT1 directly disrupts the material-supply system in myofibroblasts by starving them of proline, a critical amino acid that makes up approximately 20 percent of collagen. Because BCAT1 is largely absent in healthy tissue and becomes active primarily in scar-forming cells, its inhibition isolates pathological fibrosis with a lower risk of off-target side effects.

Major Frameworks/Components:

• Fibrosis and Myofibroblast Activation: The biological process where specialized cells overproduce collagen to reinforce scar tissue, leading to potentially fatal tissue stiffening.
• BCAT1-Proline Pathway: The cellular mechanism activated by the BCAT1 enzyme to maintain a steady supply of the amino acid proline for large-scale collagen synthesis.
• Small Molecule Inhibition: The use of the experimental drug ERG240 to selectively block BCAT1 activity, demonstrating efficacy even when administered seven days after the initial tissue injury.

Meds for Compulsive Sexual Behavior Disorder

Photo Credit: Elsa Olofsson

Scientific Frontline: Extended "At a Glance" Summary: Pharmacotherapy for Compulsive Sexual Behavior Disorder

The Core Concept: Compulsive sexual behavior disorder is a psychological condition characterized by persistent, recurring difficulties in controlling sexual impulses and behaviors. Recent clinical trials demonstrate that the medications fluoxetine and naltrexone yield comparable reductions in these symptoms over an eight-week period.

Key Distinction/Mechanism: While both pharmacological treatments are effective, their symptom reduction trajectories differ significantly. Naltrexone, a medication utilized for substance use disorders, produces an early reduction in symptoms, whereas improvements from the antidepressant fluoxetine emerge later in the treatment cycle.

Major Frameworks/Components:

• Selective Serotonin Reuptake Inhibitors (SSRIs): The application of fluoxetine to modulate serotonin levels and gradually mitigate compulsive impulses.
• Opioid Antagonists: The use of naltrexone to target behavioral addiction pathways, yielding more rapid symptom relief.
• Temporal Trajectory Variations: The clinical observation that different pharmacological agents alter the speed and pattern of symptom remission, despite achieving similar endpoints.

Vanillin in Chronic Wound Healing

Photo Credit: Diana Polekhina

Scientific Frontline: Extended "At a Glance" Summary: Vanillin-Based Therapeutics for Wound Healing

The Core Concept: Vanillin, the primary organic compound extracted from natural vanilla pods or synthesized from clove oil and rice, is being repurposed as a functional bioactive molecule to formulate treatments for chronic wounds.

Key Distinction/Mechanism: Due to its amphiphilic molecular structure, vanillin natively interacts with reactive oxygen species, cellular membranes, and polymeric matrices, operating simultaneously as a dynamic crosslinker and a potent antioxidant, anti-inflammatory, and antibacterial agent.

Major Frameworks/Components:

• Food-to-Function Translation: The systematic transition of chemically stable, safe-for-consumption sensory additives into clinically deployable medical therapeutics.
• Polymeric Matrix Integration: The incorporation of vanillin into nanomaterials and biomedical coatings to support targeted drug delivery, particularly for complex hydrophobic compounds.
• Industrial Scalability: The utilization of abundant, low-cost synthetic small molecules to ensure supply chain robustness, commercial viability, and formulation reproducibility.

Pharmacogenomics: In-Depth Description

Pharmacogenomics is the study of how an individual's genetic makeup influences their physiological response to medications. Combining pharmacology (the science of drugs) and genomics (the study of genes and their functions), this field seeks to develop effective, safe medications and prescribing guidelines tailored to a person's specific genetic profile. Its primary goal is to optimize therapeutic efficacy and eliminate the trial-and-error approach to prescribing, thereby minimizing the risk of adverse drug reactions.